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A Selective Phosphodiesterase-4 Inhibitor Reduces Leukocyte
Infiltration, Oxidative Processes, and Tissue Damage
after Spinal Cord Injury
Feng Bao,1 Jennifer C. Fleming,1 Roozbeh Golshani,2 Damien D. Pearse,2,3 Levent Kasabov,1
Arthur Brown,1 and Lynne C. Weaver1

Abstract

We tested the hypothesis that a selective phosphodiesterase type 4 inhibitor (PDE4-I; IC486051) would attenuate
early inflammatory and oxidative processes following spinal cord injury (SCI) when delivered during the first 3
days after injury. Rats receiving a moderately severe thoracic-clip-compression SCI were treated with the PDE4-I
(0.5, 1.0, and 3.0 mg/kg IV) in bolus doses from 2–60 h post-injury. Doses at 0.5 mg/kg and 1.0 mg/kg significantly decreased myeloperoxidase (MPO) enzymatic activity (neutrophils), expression of a neutrophil-associated
protein and of ED-1 (macrophages), and estimates of lipid peroxidation in cord lesion homogenates at 24 h and
72 h post-injury by 25–40%. The 3.0 mg/kg dose had small or no effects on these measures. The PDE4-I treatment
(0.5 or 1.0 mg/kg) reduced expression of the oxidative enzymes gp91phox, inducible nitric oxide synthase, and
cyclooxygenase-2, and diminished free radical generation by up to 40%. Treatment with 0.5 mg/kg PDE4-I
improved motor function (as assessed by the Basso-Beattie-Bresnahan scale) significantly from 4–8 weeks after
SCI (average difference 1.3 points). Mechanical allodynia elicited from the hindpaw decreased by up to 25%. The
PDE4-I treatment also increased white matter volume near the lesion at 8 weeks after SCI. In conclusion, the
PDE4-I reduced key markers of oxidative stress and leukocyte infiltration, producing cellular protection, locomotor improvements, and a reduction in neuropathic pain. Early inhibition of PDE4 is neuroprotective after SCI
when given acutely and briefly at sufficient doses.
Key words: free radical; IC486051; inflammation; lipid peroxidation; phosphodiesterase type 4 inhibitor

Introduction

S

trategies to improve recovery after spinal cord injury
(SCI) fall under two broad categories based on the goals
of therapy. Some are pro-regenerative, as they promote
axon growth, sprouting, and connectivity below the lesion.
Others are neuroprotective, and some of these are immunomodulatory, as they focus on altering the inflammatory
response and reducing secondary injury. One known proregenerative strategy increases the levels of cyclic adenosine
monophosphate (cAMP) by inhibition of phosphodiesterases
(PDE; Nikulina et al., 2004; Pearse et al., 2004a). An ideal
therapy would have both pro-regenerative and neuroprotective elements. Increasing intracellular cAMP potentially has
both effects, as it can also reduce leukocyte activation (Schultz

and Folkers, 1988) and chemokine production (Zidek, 1999).
Herein we evaluate the effects of PDE4 inhibition on estimates
of intraspinal inflammation and oxidative injury, tissue
sparing, and behavioral recovery after SCI.
Inflammation after SCI leads to lesion expansion and progressive tissue damage rostral and caudal to the injury site.
Recruitment and infiltration of inflammatory neutrophils and
monocyte/macrophages leads to the irreversible destruction
of normal spinal cord tissue, and consequently contributes to
neurological deficits (Taoka et al., 1997). Activated neutrophils and monocytes/macrophages release chemokines and
cytokines, and undergo oxidative burst responses releasing
proteolytic enzymes, antimicrobial proteins, and reactive oxygen species into their surrounding environment that ultimately damage cell membranes, causing the death of neurons,
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glia, and vascular cells (Bao et al., 2004b; Bao and Liu, 2004;
Taoka et al., 1997; Weiss, 1989).
The intensity and duration of the inflammatory response
directly relates to the intracellular concentration of cAMP
(Bruno et al., 2004), a second messenger that controls many
cellular processes (Beavo and Brunton, 2002). Increased
intracellular cAMP contributes to inhibition of proinflammatory cell functions such as chemotaxis, degranulation,
superoxide anion generation, release of IL-8, and phagocytosis in neutrophils (Ottonello et al., 1995; Pearse et al., 2004a;
Pryzwansky and Madden, 2003; Rossi et al., 1998). Furthermore, monocyte adhesion and migration are inhibited by high
cAMP levels, as are phagocytosis and nitric oxide production
in macrophages (Aronoff et al., 2005; Rossi et al., 1998; Zhu
et al., 2001). Increased cAMP reduces adhesion molecule
(CD11b/CD18/L-selectin) expression on leukocytes, and
leukocyte adhesion to other cells, and disrupts chemokineinduced chemotaxis (Derian et al., 1995; Harvath et al., 1991).
The predominant form of PDE in leukocytes appears to
belong to the rolipram-sensitive PDE4 isozyme group (Verghese
et al., 1995). Indeed rolipram is a well studied PDE4 inhibitor, and has been shown to inhibit leukocyte functions, including leukotriene production by monocytes, and to have
anti-inflammatory effects in vivo that include inhibition of
neutrophil migration (Griswold et al., 1993). These findings
indirectly demonstrate a role for PDE4 in several functions of
monocytes and neutrophils. Furthermore, the PDE4B subtype
has been identified, using immunocytochemistry, in activated
microglia of the injured spinal cord (Whitaker et al., 2008).
Targeted inhibition of the PDE type 4 (PDE4), is a potentially
powerful tool (Houslay and Adams, 2003), as PDE4 inhibitors
suppress the production of TNF-a, the generation of reactive
oxides, and the migration of neutrophils (Giembycz, 2000;
Torphy, 1998). Rolipram has been shown to decrease the
production of TNF-a in homogenates of the injured spinal
cord and in activated human mononuclear cells (Pearse et al.,
2004a; Semmler et al., 1993). The anti-inflammatory actions of
PDE inhibitors such as rolipram are currently being considered as therapeutics for diseases such as asthma, chronic obstructive pulmonary disease, and rheumatoid arthritis
(Giembycz, 2000; Torphy, 1998). Relevant to our study, rolipram delivery in the first 72 h after SCI in rats had neuroprotective effects, sparing oligodendrocytes from death at
27 h post-injury, an effect that may have involved abrogation
of local inflammation (Whitaker et al., 2008). Rolipram has
been used in combination with cellular transplant therapies,
yielding cellular sparing and improved motor outcomes with
the combination treatment, and in some studies with 2 weeks
of rolipram treatment alone (Beaumont et al., 2009; Bretzner
et al., 2010; Koopmans et al., 2009; Pearse et al., 2004a). These
studies suggest neuroprotective effects of the early administration of this PDE4 inhibitor. Others have demonstrated the
effectiveness of rolipram to promote regeneration after spinal
cord injury due to its important actions to block growth cone
collapse (Nikulina et al., 2004; Pearse et al., 2004a). The work
with rolipram highlights the potential for use of a PDE4 inhibitor as a neuroprotective agent and to promote regeneration after SCI.
These promising findings prompted us to undertake a
study of the effects of PDE4 inhibition for 3 days after compression SCI on the intraspinal inflammatory response and
oxidative injury within the first 3 days after injury, and also to
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examine effects of this 3-day treatment on tissue sparing and
behavioral outcomes assessed from 2–8 weeks after injury.
Our goal was to establish effects that could likely be attributed
only to the early neuroprotective or anti-inflammatory effects
of PDE4 inhibition. Because rolipram is known to have noxious side effects (Beaumont et al., 2009; Koopmans et al.,
2009), and in our pilot and published studies (Pearse et al.,
2004a), we have noted adverse side effects in rats during rolipram treatment, we elected to test a newly formulated PDE4
inhibitor, IC486051, developed by the former ICOS Corporation (Bothell, WA). IC486051 is a highly selective and potent
inhibitor of PDE4 (PDE4-I), and it inhibits all four PDE4 isoforms (A–D), with an IC50 value of 0.6 nM against recombinant human PDE4 (ICOS Corp.; Nishiguchi et al., 2007;
Snyder et al., 2005). It has a selectivity of * 10,000-fold for
PDE4 compared to other PDE isozymes. In our experiments,
IC486051 produced no noticeable adverse side effects in the
rats. A range of doses of this PDE4-I was delivered intravenously for 72 h after SCI in the rat. We demonstrated that
acute administration of the PDE4-I IC486051 reduced the
early influx of leukocytes into the injured spinal cord, limited
free radical formation and tissue damage, and provided
neurological improvement in a dose-sensitive manner.
Methods
Spinal cord injury and PDE4 inhibitor treatment
All protocols for these experiments were conducted in accordance with the policies established by the Canadian
Council on Animal Care. Female Wistar rats (n = 65; Charles
River, St. Constant, Quebec, Canada) were used in the assessment of inflammatory and oxidative processes. In our
experience, female rats have significantly fewer complications
with bladder function than do males, and accordingly we use
females whenever possible to avoid that confounding factor.
Male Wistar rats (n = 23) were used to study locomotor function and mechanical allodynia as we, like others, have found
that they have a more consistent development of allodynia
than do females (Christensen et al., 1996; Oatway et al., 2005).
The males were also used to assess histological cord damage
at 8 weeks after SCI. In our previous studies the inflammatory
response in male rats was similar to that in females (Mabon
et al., 2000; Saville et al., 2004). Details of numbers of animals
per group are shown in Table 1.
All rats were medicated with diazepam (3.5 mg/kg IP;
Sabex International, Boucherville, Quebec, Canada) and atropine (0.05 mg/kg SC; Sigma-Aldrich, St. Louis, MO), and
then anesthetized with halothane as described previously
(Weaver et al., 2001). The T4 spinal cord segment was exposed
by a dorsal laminectomy and injured, without disrupting the
dura, by a 60-sec, 35-g clip compression (Weaver et al., 2001).
Post-injury adequate measures were taken to minimize pain
and discomfort. As required by the University of Western
Ontario animal care protocol, the analgesic buprenorphine
(0.05 mg/kg; Schering-Plough Ltd., Welwyn Garden City,
Hertfordshire, U.K.) was administered immediately after
surgery and twice daily for the following 3 days. Further
treatment with analgesics was never required. Post-operative
care included antibiotics (Baytril 50 mg/mL SC; Bayer Inc.,
Toronto, Ontario, Canada), and subcutaneous hydration with
0.9% normal saline daily for 3 days. The animals were housed
on extra bedding to prevent the development of pressure and
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Table 1. Details of Numbers of Rats Used in Each Experiment of the Study
MPO assay
Uninjured
SCI
24 h
Control
13
PDE4-I 0.5 mg/kg
4
1.0 mg/kg
5
3.0 mg/kg
4
ED-1 Western blot
Uninjured
SCI
24 h
Control
13
PDE4-I 0.5 mg/kg
4
1.0 mg/kg
5
3.0 mg/kg
4
Neutrophil Western blot
Uninjured
SCI
24 h
Control
12
PDE4-I 0.5 mg/kg
4
1.0 mg/kg
4
3.0 mg/kg
4
Neutrophil and ED-1 staining at 72 h
Control
PDE4-I 0.5 mg/kg
TBARS assay
Uninjured
SCI
24 h
Control
13
PDE4-I 0.5 mg/kg
4
1.0 mg/kg
5
3.0 mg/kg
4

HNE Western lot
7
72 h
14
5
5
4
6
72 h
14
5
5
4
4
72 h
12
4
4
4
2
2
6
72 h
14
5
5
4

Uninjured
SCI
Control
PDE4-I 0.5 mg/kg
1.0 mg/kg
DCF assay
Uninjured
SCI
Control
PDE4-I 0.5 mg/kg
1.0 mg/kg
gp91phox/ iNOS Western blot
Uninjured
SCI
Control
PDE4-I 0.5 mg/kg
1.0 mg/kg
COX-2 Western blot
Uninjured
SCI
Control
PDE4-I 0.5 mg/kg
1.0 mg/kg
BBB/pain 1–8 weeks
Control
PDE4-I 0.5 mg/kg
PDE4-I 1.0 mg/kg
Histology at 8 weeks
Control
PDE4-I 0.5 mg/kg

6
24 h
8
4
4

72 h
10
5
5
6

24 h
10
5
5

72 h
10
5
5
6

24 h
9
4
5

72 h
10
5
5
6

72 h
10
5
5
11
6
6
5
5

In the biochemical studies the uninjured group had 7 rats in total; the SCI control group had 27 rats in total (13 at 24 h and 14 at 72 h). A
subset of controls was done together with each treatment dose group so that the number of controls equaled the number of PDE4-I-treated
rats in each assay. PDE4-I group totals were 27: 0.5 mg/kg (4 rats at 24 h, 5 at 72 h), 1.0 mg/kg (5 rats at 24 h, 5 at 72 h), and 3.0 mg/kg (4 rats
at 24 h, 5 at 72 h). Four additional rats were used for neutrophil and ED-1 staining.
The BBB and pain scoring was done in the same 23 rats. Of the 11 controls, 6 were done with the 0.5-mg/kg treatment and 6 with the 1.0mg/kg treatment. The rats used for histological analysis at 8 weeks were among those tested for neurological outcome. Only 5 rats per group
could be analyzed due to technical problems with one spinal cord in each group.
PDE4-I, phosphodiesterase type 4 inhibitor; TBARS, thiobarbituric acid reactive substances; SCI, spinal cord injury; COX-2,
cyclooxygenase-2; iNOS, inducible nitric oxide synthase; DCF, 2¢-7¢-dichlorofluorescein; MPO, myeloperoxidase; BBB, Basso-BeattieBresnahan rating scale; HNE, 4-hydroxynonenal.

friction sores. Urinary bladders were manually emptied by
abdominal compression twice daily until spontaneous voiding returned at 7–10 days.
The rats received post-SCI intravenous bolus injections of
the PDE4 inhibitor (PDE4-I) IC486051 (0.5 mg/kg, 1.0 mg/kg,
or 3.0 mg/kg IV in 30% DMSO, a gift of the ICOS Corporation) or vehicle alone as a control according to two protocols:
(1) at 2 h and 12 h after SCI (the rats were terminated at 24 h) or
(2) at 2, 12, 24, 36, 48, and 60 h after SCI (the rats were terminated at 72 h or 8 weeks). Due to suboptimal efficacy, the
3.0-mg/kg dose was not tested at 8 weeks after SCI. For the
behavioral studies, one cohort was tested at the 0.5-mg/kg
dose, and a second at a different time at the 1.0-mg/kg dose.
The interval between injections was determined by the halflife of the PDE4-I in rats, which is approximately 12 h (ICOS,
unpublished information). The duration of treatment was
planned to protect the cord from the peak influx of neutro-

phils after SCI, and from the first wave of monocytes/
macrophages, a strategy that we have used successfully for
other treatments (Saville et al., 2004). The drug dosing (0.05–
3.0 mg/kg) was established empirically in a pilot study that
examined the intraspinal influx of neutrophils and monocytes.
We received guidance from previous studies showing that
IC486051 inhibits PDE4 activity and has functional effects in an
ex vivo model of urinary bladder dysfunction (Snyder et al.,
2005), and that a 1.0-mg/kg dose is effective in vivo in a rat
bladder overactivity model (Nishiguchi et al., 2007). Pharmacokinetic analysis of the 1.0-mg/kg dose by Nishiguchi and
associates (2007) revealed that the plasma concentrations
reached by this dose in rats would be selective for PDE4. Given
the selectivity of IC486501, our 3.0-mg/kg dose would also
target only PDE4. We tested no doses greater than 3 mg/kg, as
this dose was marginally effective. All aspects of testing and
data analysis employed a blinded design. To accomplish this,
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the vials containing either the PDE4-I or vehicle were numbered following a code generated by a staff member who did
not work on the study. The code was revealed only after all
data were analyzed. Rats treated with IC486051 or the vehicle
ate and drank normally, moved in their cages typically for
cord-injured rats, gained weight following normal patterns,
and showed no evidence of toxic side effects of the treatment.
Assessment of intraspinal inflammatory cells
Intraspinal inflammatory cells were detected by immunohistochemical staining of neutrophils and macrophages in
spinal cord, and quantified by myeloperoxidase (MPO) assays and Western blotting of neutrophil and macrophage
markers in homogenates of the T2–T6 cord as described previously (Bao et al., 2004b). Briefly, for the histological study,
the animals were perfused at 72 h after SCI with cold saline,
followed by 4% paraformaldehyde. A 1-cm segment of cord
centered at the injury zone (T4) was removed and post-fixed
in the same fixative for another 24 h at 4C, cryoprotected in
increasing concentrations of sucrose (10%, 20%, and 30% in
PBS), and sectioned into 25-lm longitudinal sections. The
neutrophils were detected by a rabbit anti-rat neutrophil
antibody (1:20,000, a gift of Dr. Daniel Anthony, Oxford
University, Oxford, U.K.), and the macrophages were detected by a monoclonal antibody to ED-1 (1:2000; Serotec,
Oxford, U.K.).
MPO enzymatic activity (mostly from neutrophils and
weakly from macrophages), neutrophil antigen expression,
and ED-1 expression (from macrophages and microglia) were
measured from homogenates of the T2–T6 cord as described
previously (Bao et al., 2004b). Although MPO can be found in
macrophages, immunohistological studies in cord-injured
rats have shown that at 24 h and 72 h after SCI, MPO immunoreactivity is found intensely in cells with morphology
typical of neutrophils, and only weakly in macrophages
(Fleming et al., 2008). ED-1 immunoreactivity is seen exclusively in microglia and macrophages. For Western blotting,
protein derived from spinal cord homogenates was loaded
onto a 7% or 10% polyacrylamide gel and separated by SDSPAGE using a Bio-Rad Mini-Protean 3 apparatus (Bio-Rad,
Hercules, CA), then transferred to polyvinylidene difluoride
(PVDF) membranes (0.45-lm pore size; Millipore, Mississauga, Ontario, Canada). The membranes were first
blocked with 5% nonfat powdered milk, and then incubated
with a primary antibody, anti-ED-1 (1:2000; Serotec), or antirat neutrophil antibody (1:20,000, a gift of Dr. Anthony),
followed by incubation with horseradish peroxidase (HRP)conjugated donkey anti-mouse secondary antibody. The signal was developed using the enhanced chemiluminescence
(ECL plus) detection system (Amersham, Oakville, Ontario,
Canada). Band intensity was measured using Lab Works
software (UVP, Upland, CA). The membrane was then incubated in stripping buffer and re-probed with anti-b-actin
(1:10,000; Sigma-Aldrich) mouse monoclonal antibody. The
signal was developed as described above. The densitometric
values of the neutrophil antigen or ED-1 were normalized
against b-actin to control for variation in protein loading.
Assessment of lipid peroxidation
Malondialdehyde (MDA) is used as a marker for lipid
peroxidation, and was quantified in the homogenates of the
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T2–T6 spinal cord segment using a thiobarbituric acid reactive
substances (TBARS) assay as described previously (Bao et al.,
2004b). A standard curve was established using MDA bis
(dimethyl acetal; Sigma-Aldrich), and lipid peroxidation was
expressed as nanomoles of TBARS/g tissue. Lipid peroxidation was also detected by the presence of 4-hydroxynonenal
(HNE)-bound proteins in Western blots, using an anti-HNE
monoclonal antibody (1:5000; Alpha Diagnostic International,
San Antonio, TX) and 10% polyacrylamide gels.
Assessment of free radical formation
and oxidative enzymes
We used 2¢-7¢-dichlorofluorescin diacetate (DCFH-DA) as
a probe to assess free radical production. An aliquot of the
same sample (25 lL) from the homogenates of the T2–T6
spinal cord segment was incubated with 0.1 mM DCFH-DA
at 37C for 30 min. DCFH-DA is hydrolyzed to DCFH because the diacetate group is cleaved by esterases. DCFH is
then oxidized by the reactive oxygen species to form the
fluorescent compound, 2¢-7¢-dichlorofluorescein (DCF). The
DCF formation was monitored at an excitation wavelength
of 488 nm and an emission wavelength of 525 nm using a
fluorescence spectrophotometer as described previously
(Bao et al., 2005). Background fluorescence was corrected
by the inclusion of parallel blanks. The formation of reactive oxygen species was quantified using a DCF standard
curve, and results were expressed as nanomoles DCF/mg
protein.
The levels of iNOS, cyclooxygenase-2 (COX-2), and
gp91phox protein expression in the T2–T6 spinal cord were
quantified by Western blot analysis using either 7% or 10%
polyacrylamide gels. Western blots of protein derived from
spinal cord homogenates were probed at room temperature
with antibodies to iNOS (1:5000; Calbiochem, San Diego, CA),
COX-2 (1:2000; Cayman Chemical, Ann Arbor, MI), or
gp91phox (1:1000; BD Biosciences Pharmingen, Lexington, KY)
overnight, followed by incubation with HRP-conjugated antirabbit or donkey anti-mouse secondary antibodies. Membranes were also probed with an anti-b-actin antibody to
control for variations in protein loading.
Locomotor function
The rats were acclimated to the behavioral room where
locomotor testing was done for 3 days prior to SCI and
treatment. Locomotor recovery of the animals was assessed
from 3 days to 8 weeks after SCI by two independent observers using the 21-point Basso-Beattie-Bresnahan (BBB)
open field locomotor score (Basso et al., 1995). Testing was
performed twice per week, and scores were averaged to
generate a weekly score. Scores of left and right hindlimbs
were averaged. Higher scores (14–21) on this scale require
demonstration of fine details of locomotion. The severity of
injury in our studies never permitted the rats to achieve locomotion scores in the range 14–21. At 1 week after injury all
rats had very low scores of approximately 1, demonstrating
the intended severity of injury. For the next 2 weeks the rats
showed high individual animal variability in the rate of improvement, particularly in the control group. This variability
abated at 4 weeks after injury, and data collection for analysis
continued at this time. As described above, the observers were
blinded regarding the treatment of the animals.
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Mechanical allodynia
The rats were tested for the presence of mechanical allodynia
on the hindpaws before, and 2–6 weeks after SCI as described
elsewhere (Oatway et al., 2005). Briefly, 1 or 2 days before SCI,
the rats were acclimated for 20 min in the acrylic glass testing
chamber (8 · 3.5 · 3.5 inches), consisting of plastic mesh walls
and an elevated mesh floor. Pre-injury responses were determined the day before SCI, and then beginning 2 weeks after SCI,
the rats were tested once per week. When testing commenced,
the rats were placed in this chamber and stimulated 10 times on
the plantar surface of the hindpaw using a 15-mN modified
Semmes-Weinstein monofilament. Each stimulus lasted 3 sec
and was separated by a 5-sec interim period. After the testing of
one hindpaw, a 2-min interim period lapsed before the second
hindpaw was tested. The number of avoidance responses to the
10 stimuli for each hindpaw was tabulated, and the mean
number of avoidances elicited from both hindpaws was calculated. Flinching, escape, paw withdrawal and/or licking, vocalization, and biting at the filament indicated that the rat
perceived the stimulus as noxious. Prior to SCI, this stimulation
never elicited avoidance responses. Again, the observers were
blinded regarding the treatments the animals had received.
Histological assessment
At 8 weeks after SCI, the rats were transcardially perfused
with 4% paraformaldehyde, and a 10-mm spinal cord portion
encompassing the injury epicenter was extracted and embedded in paraffin for coronal sectioning at 10 lm on a microtome.
Every fourth section was mounted onto a series of five slides.
One series was used for immunohistochemical staining with
the neuron-specific marker NeuN to permit stereological
quantification of neuron numbers according to previously described methods (Schaal et al., 2007). After removing the paraffin from the sections, they were rehydrated through a series
of xylene and ethanol exposures. Antigen retrieval with citrate
buffer at 96C was performed for 20 min, after which the slides
were cooled to room temperature and rinsed in PBS. The sections were blocked with 5% heat-inactivated goat serum
(HINGS) in PBS for 1 h at room temperature, and incubated
overnight at 4C with neuron-specific mouse monoclonal antibody, NeuN (1:400; Chemicon, Temecula, CA). The sections
were rinsed three times with PBS, and then incubated for 2 h
with a biotin-conjugated goat anti-mouse secondary antibody
(1:1000; Santa Cruz Biotechnology, Santa Cruz, CA). The sections were washed with PBS, and incubated with streptavidin
HRP for 1 h. An immunoperoxidase substrate reaction was
used to develop and visualize immunoreactive cells (Vector
Laboratories, Inc., Burlingame, CA), and a methyl blue counter-stain was used to identify cell nuclei.
Stereological quantification of neuronal preservation
Sections immunostained for NeuN were examined under
200 · magnification using an Olympus BX 51 microscope for
stereological quantification of preserved neurons, using Stereoinvestigator 7 (MicroBrightField Bioscience, Williston, VT),
as employed previously (Pearse et al., 2005). Final cell counts
were expressed as numbers of estimated profiles per mm3. A
coefficient of error (R.L. Shaeffer) was calculated to assess the
accuracy of these stereological estimates. For the optical fractionator tool, a grid size of 80 lm · 80 lm and a counting
frame of 75 lm · 75 lm was used to count the cells. NeuN-

1039

immunoreactive neurons were counted within the entire gray
matter (Pearse et al., 2005) from every third coronal section
(600-lm intervals) of the T3–T5 spinal cord segment. This
yielded analyses from 10 coronal sections per spinal cord.
Analysis of tissue integrity
Hematoxylin and eosin (H&E), and Luxol fast blue-stained
sections (400-lm intervals) of the T3–5 cord were used to
quantify volumes of normal-appearing gray and white matter
within the spinal cord and lesion volumes using computerassisted microscopy and image analysis software (Neurolucida
5.04.3; MicroBrightField) at a magnification of 400 · as described elsewhere (Pearse et al., 2005). Accordingly 15 sections
were analyzed from each spinal cord. In each section, the perimeter (contour) of the total spinal cord section, the normalappearing gray matter, and the normal-appearing white matter
were separately traced on live images. Normal-appearing gray
matter was distinguished from damaged tissue by the presence
of healthy neurons and normal cellular density (without the
presence of numerous nuclei, which is indicative of immune cell
infiltration). Normal-appearing white matter was defined as
being non-fragmented, dark Luxol fast blue staining (not pale
blue), and without immune cell infiltration (Pearse et al., 2004b).
Each traced section was logged into the Neurolucida software
by using a serial section manager, which tracked the position of
each section within the 4-mm-long Z-stack to allow volume
calculations with NeuroExplorer algorithms. The total spinal
cord volume and the volumes of normal-appearing gray and
white matter from the spinal cord piece were determined by the
software. These volumes in the control and treated SCI groups
were similar. Lesion volume was calculated by subtracting
preserved tissue volumes from the total cord volume. Four
control and five treated samples were used for these analyses.
Statistical analysis
Mean values are expressed as – standard error (SE). Results
were subjected to parametric statistical analysis using analysis
of variance (ANOVA; Snedecor and Cochran, 1989). A oneway ANOVA was used to analyze locomotor scores and
hindpaw withdrawal responses, as these measures reached a
plateau with time, and changes with time and treatment did
not interact. One-way ANOVA was also used for comparison
of marker expression and activity associated with leukocyte
infiltration and oxidative stress, as well as histopathological
parameters. Differences between means were determined by
Student-Neuman-Keuls (SNK) testing. Analysis of the histological tissue sparing was done by Student’s t-tests. Significance was accepted at p < 0.05. p Values given in the results
section for all but the histological data refer to the values
obtained in the SNK test following the ANOVA. Details of the
ANOVA are provided in the figure legends. All analyses were
done with the investigators blinded to the treatment the rats
had received.
Results
PDE4-I treatment reduces intraspinal neutrophils
and macrophages after SCI
Rats were treated with PDE4-I at three different doses (0.5,
1.0, and 3.0 mg/kg), delivered in bolus doses at 2 and 12 h
after SCI (effects were assessed at 24 h), or at 12-h intervals up
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activity in all groups of SCI rats remained greater than that in
the uninjured rats. The treatment effects on MPO activity did
not differ significantly by dose.
To complement the MPO assay, the presence of neutrophils
in the cord was quantified using an anti-neutrophil antibody
in a Western blot analysis. Neutrophil protein (molecular
weight 56 kDa) expression was low in uninjured spinal cord
homogenates (Fig. 1B), but increased significantly at 24 and
72 h after SCI. Treatment with 0.5 mg/kg PDE4-I significantly
reduced neutrophil protein expression, by 52% ( p = 0.002) at
24 h, and by 57% ( p = 0.038) at 72 h after injury compared to
SCI controls. The 1.0-mg/kg dose of PDE4-I significantly reduced neutrophil protein expression only at 24 h post-injury
( - 45%, p = 0.016). The 3.0-mg/kg dose did not reduce protein
expression at either sampling time point. When effects of
different PDE4-I doses on neutrophil infiltration were compared, the effects of the 0.5-mg/kg and 1.0-mg/kg doses were
not different at 24 h or 72 h post-injury. However, at 72 h postinjury the 0.5-mg/kg dose tended to have a greater effect on
the neutrophils than the 3.0-mg/kg dose ( p = 0.09, Fig. 1B). No
difference was found among the three doses at 24 h postinjury. Like the MPO assay, the neutrophil antigen expression
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to 60 h after injury (effects were assessed at 72 h). The effect of
this PDE4-I treatment on neutrophil influx and macrophage
activation after SCI was quantified using an MPO activity
assay. MPO enzymatic activity (6.90 – 0.02 units/g tissue) was
minimal in the uninjured spinal cord (Fig. 1A). At 24 and 72 h
after SCI, MPO activity in the T2–T6 cord of the control SCI
group increased significantly (by 11-fold at 24 h; by eightfold
at 72 h) compared to the uninjured controls. Treatment with
0.5 mg/kg PDE4-I significantly reduced MPO activity ( - 44%,
p = 0.002 and - 38.3%, p = 0.018) at both 24 h and 72 h postinjury compared to the SCI controls. At 1.0 mg/kg, the PDE4-I
significantly reduced MPO activity at both 24 h and 72 h postinjury ( - 29.8%, p = 0.024 and - 39.1%, p = 0.017, respectively).
After 3.0 mg/kg PDE4-I, MPO activity was reduced significantly only at 24 h post-injury ( - 23.8%, p = 0.038, Fig. 1A).
Whereas the PDE4-I treatments reduced MPO activity, they
did not return it to levels found in uninjured rats, as MPO
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FIG. 1. Phosphodiesterase type 4 inhibitor (PDE4-I) treatment decreases intraspinal neutrophil and monocyte/
macrophage influx at 24 h and 72 h after SCI. (A) Myeloperoxidase (MPO) activity in cord homogenates increased
after injury in control rats (n = 4/5 per group to match treated
rat numbers), and in the PDE4-I-treated rats compared to
uninjured rats (n = 7). These increases were significantly
smaller in the PDE4-I-treated rats than in controls at the
doses of 0.5 mg/kg or 1.0 mg/kg at 24 h and 72 h post-injury
(n = 4–5/group; see Table 1), and 3.0 mg/kg at 24 h (n = 4/
group), but not 72 h (n = 4/group) after SCI (analysis of
variance [ANOVA] F12,50 = 19.08, p < 0.001; Student-NeumanKeuls [SNK] test, p < 0.05). Values are means – standard error
(SE; *significantly different from control injured). All groups
were significantly different from uninjured (SCI, SCI control
injured; SCI + PDE4-I, treated injured). (B) Neutrophil protein, as identified by Western blotting, in cord homogenates
and expressed in arbitrary units (A.U.), increased after injury
in control rats and in the PDE4-I-treated rats compared to
uninjured rats (n = 4 for all groups). Representative autoradiograms of Western blots are shown in the bottom panel (U,
uninjured; S, SCI, injured; S + I, injured + treated). These increases were significantly smaller in the PDE4-I-treated rats
than in controls at the doses of 0.5 mg/kg or 1.0 mg/kg at
24 h post-injury, and 0.5 mg/kg at 72 h after SCI (ANOVA,
F12,39 = 8.5, p < 0.001; by SNK test p < 0.05). The MPO activity
at 72 h post-injury in the 0.5-mg/kg treatment group tended
to be smaller that in the 3.0-mg/kg treatment group
( p = 0.09). Values are means – SE (*significantly different
from control injured; #tended to differ from 3.0-mg/kg
PDE4-I treated at 72 h). All groups were significantly different from uninjured animals. Abbreviations as above. (C)
Photomicrographs of longitudinal sections of spinal cord
immunostained by an anti-neutrophil antibody. The sections
from control injured (panels C1 and C3), and 0.5-mg/kg
PDE4-I-treated rats (panels C2 and C4) at 72 h following T4
clip compression injury. Panels C3 and C4 show detail of
area indicated by the arrows in panels C1 and C2, respectively (scale bar = 500 lm in C1 and C2 and 100 lm in C3 and
C4). The section from the PDE4-I-treated rat appears to have
fewer neutrophils.
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FIG. 2. Phosphodiesterase type 4 inhibitor (PDE4-I) treatment decreases intraspinal monocyte/macrophage influx at 24 h
and 72 h after SCI. (A) Western blotting with ED-1, expressed in arbitrary units (A.U.), in cord homogenates (n = 4–6/group;
see Table 1) showed an increase at 24 and 72 h after SCI compared to uninjured cords; these increases were reduced by PDE4I administration (analysis of variance [ANOVA] F12,39 = 11.26, p < 0.001; Student-Neuman-Keuls [SNK] test p < 0.05). A
representative autoradiogram of a Western blot is shown in the bottom panel Values are means – standard error (SE;
*significantly different from control injured; #significantly different from 3-mg/kg PDE4-I treated at 72 h; all groups were
significantly different from uninjured animals; U, uninjured; S, SCI control injured; S + I, PDE4-I-treated injured; SCI + PDE4-I,
treated injured). (B) Photomicrographs of longitudinal sections of spinal cord immunostained by an anti-ED1 antibody. The
sections from control injured (A and C), and PDE4-I-treated rats (0.5 mg/kg, B and D) at 72 h following T4 clip-compression
injury. C and D show detail of area indicated by the arrows in A and B, respectively (scale bars = 500 lm in A and B, and
100 lm in C and D). The section from the PDE4-I-treated rat appears to have fewer monocytes/macrophages.

1042
in the injured spinal cords remained greater than in uninjured
rats after all PDE4-I treatments.
To corroborate the Western blot results the anti-neutrophil
antibody was used to identify neutrophils in the injured spinal cord. At 72 h after SCI, many cells that were stained by the
anti-neutrophil antibody were detected in the lesion site of the
spinal cord (Fig. 1 panels C1 and C3), and after PDE4-I
treatment (0.5 mg/kg) the density of these cells appeared to be
reduced (Fig. 1 panels C2 and C4).
The presence of phagocytic macrophages in the injured
spinal cord was estimated using Western blot analysis for ED1 expression (molecular weight 110 kDa) in cord homogenates. ED-1 expression was low in uninjured spinal cord
(Fig. 2A), but increased significantly at 24 and 72 h after SCI.
Treatment with 0.5 mg/kg PDE4-I significantly reduced ED-1
expression ( - 34%, p = 0.014 and - 27%, p = 0.039) at both 24 h
and 72 h after injury compared with SCI controls. A dose of
1.0 mg/kg of the PDE4-I also significantly reduced ED-1 expression at both 24 and 72 h post-injury ( - 34%, p = 0.015 and
- 36%, p = 0.004, respectively). Like MPO activity, 3.0 mg/kg
PDE4-I only reduced ED-1 expression at 24 h post-injury
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( - 29%, p = 0.021). When the effects of different PDE4-I doses
on macrophage infiltration were compared, the 0.5-mg/kg
and 1.0-mg/kg doses were not different at 24 h or 72 h postinjury. However, significant differences were found between
the 0.5-mg/kg and 3.0-mg/kg doses ( p = 0.05) at 72 h postinjury, and between the 1.0-mg/kg and 3.0-mg/kg doses
( p = 0.029) at 72 h post-injury (Fig. 2A). No difference was
found among the three doses at 24 h post-injury. To corroborate the Western blot results, an anti-ED-1 antibody was
used to identify macrophages in the injured spinal cord. At
72 h after SCI, many ED-1-immunoreactive (IR) cells were
detected in the lesion site of the spinal cord (Fig. 2B), and after
PDE4-I treatment (0.5 mg/kg) the density of these cells clearly
appeared to be reduced (Fig. 2B).
Lipid peroxidation after SCI decreases
with PDE4-I treatment
Next, effects of these doses of PDE4-I on spinal cord lipid
membrane damage were evaluated by examining lipid peroxidation (malondialdehyde) in homogenates of the injured

FIG. 3. Phosphodiesterase type 4 inhibitor (PDE4-I) treatment decreased lipid peroxidation in spinal cord homogenates at
24 and 72 h after spinal cord injury (SCI). Lipid peroxidation was assessed using the thiobarbituric acid reactive substances
(TBARS) assay for malondialdehyde. (A) TBARS concentration increased significantly in controls (n = 4–5 to match numbers
in the treated groups), and the PDE4-I-treated rats (n = 4–5; see Table 1), when compared to that in the cords of uninjured rats
(n = 6). In rats treated with PDE4-I at the 0.5-mg/kg and 1.0-mg/kg doses, the increases were significantly smaller than those
of controls at 24 and 72 h after injury (analysis of variance [ANOVA] F12,49 = 13.69, p < 0.001; Student-Neuman-Keuls [SNK]
test p < 0.05). After the 3.0-mg/kg dose (n = 4) the TBARS concentration was not significantly changed. The TBARS concentration at 24 h after injury in the 1.0-mg/kg treatment group tended to be smaller than that in the 3.0-mg/kg group
( p = 0.08). Lipid peroxidation was also assayed by Western blotting for 4-hydroxynonenol (HNE, B, n = 4–6/group; see Table
1), and the PDE4-I treatment reduced HNE protein damage significantly (ANOVA F8,27 = 44.56, p < 0.001; SNK test p < 0.05).
Western blots illustrate HNE-bound protein expression compared to loading controls (b-actin). Values are means – standard
error (SE). All groups were significantly different from uninjured animals (*significantly different from SCI controls; tended
to differ from 3-mg/kg PDE4-I-treated at 24 h; U, uninjured; S, SCI control injured; S + I, PDE4-I-treated injured; SCI + PDE4-I,
treated injured).
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cord. Lipid peroxidation, as assessed by the amount of TBARS
in the cord homogenate, was minimal in the uninjured spinal
cord (79 – 6 nmol TBARS/g tissue; Fig. 3A). The TBARS concentration was significantly increased (by 3.6–4.4-fold) in SCI
controls at 24 and 72 h after injury (285–350 nmol/g tissue).
Treatment with 0.5 mg/kg PDE4-I significantly reduced
TBARS levels at 24 h after SCI ( - 38%, p = 0.012), but not at
72 h. Administration of 1.0 mg/kg PDE4-I significantly reduced TBARS levels ( - 35%, p = 0.005 and - 28%, p = 0.059) at
24 and 72 h, respectively, after SCI. The 3.0-mg/kg dose did
not significantly reduce lipid peroxidation at 24 h or 72 h after
SCI (Fig. 3A). When examining the dose response for this
treatment using the TBARS concentration as an end-point, we
found no significant difference between doses at 24 h or 72 h
post-injury. The effects of 1.0 mg/kg tended to be greater than
those of 3.0 mg/kg at 24 h post-injury ( p = 0.08, Fig. 3A). As
the highest dose of the PDE4-I (3 mg/kg) had less consistent
effects on inflammation and intraspinal damage after SCI than
the lower doses, we examined the 0.5- and 1.0-mg/kg doses
on additional measures of lipid peroxidation, oxidative activity, functional outcomes, and histological damage of the
injured cord.
The effects of 0.5 and 1.0 mg/kg PDE4-I on lipid peroxidation were also measured by the analysis of HNE-modified
proteins using Western blotting. Very little HNE-modified
protein was observed in the uninjured spinal cord (Fig. 3B).
SCI, however, led to the modification of proteins both at 24
and 72 h after injury. Treatment with 0.5 mg/kg PDE4-I significantly decreased SCI-induced HNE protein modification
( - 26%, p < 0.001 and - 17%, p = 0.002, respectively) at both
24 h and 72 h post-injury. The PDE4-I at 1.0 mg/kg reduced
HNE protein modification at both 24 and 72 h after SCI
( - 29%, p < 0.001 and - 38%, p < 0.001, respectively; Fig. 3B).
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Western blotting for iNOS revealed a band at 130 kDa that
was faint in uninjured cords (Fig. 5B). A significant increase in
iNOS protein expression (sevenfold) was observed at 24 and
72 h after SCI. Treatment with 0.5 mg/kg PDE4-I significantly
decreased iNOS expression ( - 29%, p < 0.001 and - 39%,
p < 0.001, respectively) at both 24 h and 72 h post-injury. The
administration of 1.0 mg/kg PDE4-I significantly reduced
iNOS expression at both 24 and 72 h post-injury ( - 46%,
p < 0.001 and - 40%, p < 0.001, respectively), compared to SCI
controls (Fig. 5B).
COX-2 was identified at a molecular weight of 72 kDa,
again with very low expression in uninjured controls (Fig.
5C). At 72 h after SCI, COX-2 expression significantly increased, by eightfold, and treatment with 0.5 mg/kg and
1.0 mg/kg PDE4-I significantly reduced COX-2 ( - 25%,
p = 0.016 and - 15%, p = 0.041, respectively) compared to the
SCI controls (Fig. 5C).
PDE4-I treatment improves motor function after SCI
The 0.5- and 1.0-mg/kg doses of PDE4-I that had demonstrated the most robust anti-inflammatory and antioxidant
effects were used to evaluate effects on locomotor performance using the BBB scoring method (Basso et al., 1995). The
0.5-mg/kg dose of PDE4-I produced a significant improvement in BBB scores that persisted from 4–8 weeks post-injury
(Fig. 6A; p = 0.03–0.05). The scores differed by an average of
1.3 points during this time. A significant effect of 1.0 mg/kg
PDE4-I treatment was detected by ANOVA ( p < 0.001), but
the mean values of the control and treatment groups did not
differ significantly. The difference between the values for
control and treated rats at the 1.0-mg/kg dose during the 4- to
8-week interval averaged only 0.6 point. By interpreting these
scores, we saw that the control rats in our study were able to

Free radical formation after SCI decreases
with PDE4-I treatment
We used DCFH-DA as a probe for free radical generation
and observed low concentrations of the oxidized DCF product in uninjured cord homogenates (Fig. 4). In contrast, DCF
production in injured controls was significantly increased, by
up to fivefold ( p < 0.001), at both 24 and 72 h after SCI.
Treatment with 0.5 mg/kg PDE4-I significantly lowered DCF
concentration in the injured cord at both 24 h and 72 h after
injury ( - 29% and - 26%, p = 0.032 and p = 0.014, respectively).
The PDE4-I at 1.0 mg/kg significantly reduced DCF levels at
24 and 72 h ( - 34%, p = 0.007 and - 26%, p = 0.02, respectively;
Fig. 4).
Production of oxidative enzymes after SCI decreases
with PDE4-I treatment
Expression of the oxidative enzymes gp91phox, iNOS, and
COX-2, was detected by Western blotting. Immunoblot detection of gp91phox revealed a single band at 58 kDa in all groups,
with low expression in uninjured cords (Fig. 5A). At 24 and 72 h
after SCI, expression of gp91phox significantly increased by
fourfold compared to uninjured controls. The administration of
0.5 mg/kg PDE4-I significantly reduced gp91phox ( - 24%
p = 0.026 and - 21% p = 0.05, respectively) at 24 h and 72 h after
SCI compared to SCI controls. Delivery of 1.0 mg/kg PDE4-I
reduced gp91phox at both 24 and 72 h post-injury ( - 21%,
p = 0.014 and - 35%, p < 0.001, respectively; Fig. 5A).

FIG. 4. Phosphodiesterase type 4 inhibitor (PDE4-I) treatment decreased 2¢-7¢-dichlorofluorescein (DCF) fluorescence,
a marker of reactive oxygen species, in cord homogenates at
24 and 72 h after spinal cord injury (SCI). DCF levels increased in the injured controls (n = 5–6/group; see Table 1),
and in the PDE4-I-treated rats (n = 5/group) compared to
uninjured rats (n = 6). DCF levels, however, were significantly lower in the PDE4-I-treated rats than in controls, both
at 0.5-mg/kg and 1.0-mg/kg doses (analysis of variance
[ANOVA] F8,35 = 21.18, p < 0.001; Student-Neuman-Keuls
[SNK] test p < 0.05). Values are means – standard error
(*significantly different from controls). All groups were significantly different compared to uninjured animals.
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move their hindlimbs extensively, often in a sweeping
movement, but rarely achieved a weight-supporting stance.
The 0.5-mg/kg PDE-4-I-treated rats were able to support their
weight and to make dorsal or plantar-stepping movements
that permitted locomotion without coordination of forelimb
and hindlimb movements.
PDE4-I treatment decreases mechanical
allodynia after SCI
Mechanical allodynia is a form of neuropathic pain that
develops after neural injury in which an innocuous stimulus is
perceived as painful; in animals allodynia can be identified by
their avoidance responses to touch (Christensen et al., 1996).
Mechanical allodynia was assessed on the hindpaws both
before, and at 2–6 weeks after, SCI using a 15-mN modified
Semmes-Weinstein filament (Fig. 6B). Before SCI, the rats did
not exhibit avoidance responses to stimulation by the filament. Following SCI, control animals showed numbers of
avoidance responses to paw stimuli (maximum 3.3 – 0.3),
consistent with the development of mechanical allodynia
(Oatway et al., 2005). Administration of PDE4-I significantly
decreased the frequency of the avoidance responses to hindpaw stimulation (0.5 mg/kg, p < 0.001, maximum 2.6 – 0.6;
1.0 mg/kg, p < 0.001, maximum 2.3 – 0.4) from 4–6 weeks after
injury (Fig. 6B). At 2 weeks after SCI, the 1.0-mg/kg dose also
reduced the number of avoidance responses ( p = 0.05), and the
0.5-mg/kg dose also tended to reduce them ( p = 0.07). The
mechanical allodynia scores of rats receiving the 0.5-mg/kg
dose of PDE4-I were similar to the scores of those receiving the
higher dose.
Preservation of tissue by PDE4-I treatment
We assessed tissue sparing in the rats that had undergone
8 weeks of behavioral testing, examining the group that had
the best motor improvement (dosed at 0.5 mg/kg). Sparing
of neurons and the volume of gray matter, white matter,
and lesion size within the T2–T6 spinal cord were examined
after PDE4-I treatment and compared to SCI controls using
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FIG. 5. Phosphodiesterase type 4 inhibitor (PDE4-I) treatment decreases the production of oxidative enzymes in cord
homogenates at 24 and 72 h after spinal cord injury (SCI).
When assayed by Western blotting, expression of (A)
gp91phox, a subunit of reduced nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase (n = 4–6/group; see
Table 1), (B) inducible nitric oxide synthase (iNOS; n = 4–6/
group), and (C) cyclooxygenase-2 (COX-2; n = 4–6/group)
increased after SCI (both controls and PDE4-I-treated animals) compared to uninjured rats. See Table 1 for details of
animal numbers. These increases were significantly smaller
in the PDE4-I-treated rats than in controls with the 0.5-mg/
kg and 1.0-mg/kg doses at 24 and 72 h after SCI (analysis of
variance [ANOVA]: gp91phox F8,27 = 30.1, p < 0.001; iNOS
F8,27 = 62.2, p < 0.001; COX-2 F4,15 = 57.7, p < 0.001). All comparisons of means by Student-Neuman-Keuls test ( p < 0.05).
Representative Western blots illustrate gp91phox, iNOS, and
COX-2 expression compared to loading controls (b-actin).
Values are means – standard error (all groups were significantly different from uninjured animals; *significantly different from controls; U, uninjured; S, SCI control injured;
S + I, PDE4-I-treated injured; SCI + PDE4-I, treated injured).
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stereological quantification of cells immunoreactive for the
neuron marker NeuN and H&E-stained tissue sections at 8
weeks post-injury (Fig. 7). In the rats receiving PDE4-I treatment, overall tissue integrity at the lesion site was more intact
than in the control spinal cords (Fig. 7 top). Apparent sparing
of both gray and white matter was visible upon microscopic
inspection of the tissue sections. Indeed, PDE4-I treatment
significantly reduced the loss of white matter, as the volume
of white matter was greater than that in the controls by 38%
( p = 0.004 by Student’s t-test). Although the treatment decreased the lesion volume by 21%, this change was not significant ( p = 0.27 by Student’s t-test). In contrast, the number
of preserved NeuN-immunoreactive cells did not change
when compared with the numbers in controls ( p = 0.24
by Student’s t-test; Fig. 7 bottom). Likewise the volume of
gray matter at the lesion site did not change significantly
( p = 0.8 by Student’s t-test).
Discussion

FIG. 6. Phosphodiesterase type 4 inhibitor (PDE4-I) treatment improves locomotor function and decreases mechanical
allodynia after spinal cord injury (SCI). Basso-Beattie-Bresnahan (BBB) locomotor scores (A) were obtained from the PDE4I-treated injured rats and SCI controls twice weekly for 8
weeks. The left and right leg scores were averaged after each
test, and the two scores per week were averaged. Rats receiving the 0.5-mg/kg dose (n = 6) had BBB scores significantly greater than those of SCI controls (n = 11; see Table 1)
from 4–8 weeks after SCI (analysis of variance [ANOVA]
F11,90 = 73.5, p < 0.001; Student-Neuman-Keuls [SNK] test
p < 0.05). BBB scores for the PDE4-I-treated rats at 1.0 mg/kg
(n = 6) were not different from those of SCI controls (ANOVA
F11,90 = 78.0, p < 0.001; SNK test p < 0.05). (B) Mechanical allodynia was detected by avoidance responses to hindpaw
stimulation in SCI control rats (n = 11), and in PDE4-I-treated
injured rats (n = 6). The rats were tested once per week,
commencing at 2 weeks after SCI; scores of the left and right
hindpaws were averaged. The PDE4-I treatment caused significant decreases in avoidance responses at 1 week (1.0-mg/
kg group only) after SCI, and at 4–6 weeks (both doses) after
SCI (0.5 mg/kg ANOVA F9,75 = 45.3, p < 0.001; SNK test
p < 0.05; 1.0 mg/kg ANOVA F9,75 = 54.0, p < 0.001; SNK test
p < 0.05). Values are means – standard error (*significantly
different between control and PDE4-I-treated rats; *0.05 mg/
kg PDE4-I-treated rats tended to differ from controls, p = 0.07).

When given within the first 72 h after SCI, the PDE4-I
(IC486051) effectively decreased inflammatory cell infiltration
and activity in the injured spinal cord, reduced intraspinal
free radical formation and oxidative damage, preserved white
matter, and improved neurological function after SCI. Although the previous therapeutic use of PDE4-I inhibitors after
SCI has largely focused on their support of axonal growth,
particularly in combination with cellular implants (Bretzner
et al., 2010; Nikulina et al., 2004; Pearse et al., 2004a), the
present study shows that when acutely administered they
can also provide neuroprotection, likely through an antiinflammatory action. This finding correlates well with our
previous observations that brief, early anti-inflammatory
treatments can reduce both immune cell infiltration and oxidative damage within the injured cord, leading to improved
motor and autonomic outcomes, as well as reduced neuropathic pain after SCI (Bao et al., 2004a, 2004b; Gris et al., 2004).
It also is consistent with studies of others who noted neuroprotective effects after long-lasting treatments with rolipram
(Beaumont et al., 2009; Iannotti et al., 2010; Pearse et al., 2004a;
Whitaker et al., 2008).
All markers of inflammation and its secondary consequences examined in our study were decreased by the early
administration of the PDE4 inhibitor IC486051. Although we
did not count infiltrating neutrophils and monocyte/macrophage microglial activation, we employed Western blotting
for their proteins and enzymatic markers known to be present
almost exclusively on specific immune cell types within the
injured CNS. MPO, an oxidative enzyme largely produced by
neutrophils, ED-1, a lysosomal protein expressed by activated
macrophages and microglia (Bao et al., 2004b), and the neutrophil-associated protein were substantially reduced by
PDE4-I at 24 h and 72 h post-injury. The reduction of MPO
activity by 72 h post-injury may also be attributed in part to
effects on the influx of monocytes/macrophages into the injured cord. The first 72 h after injury coincides with the entry
and activation of these inflammatory leukocytes (Saville et al.,
2004). Immune cell activation after SCI leads to a welldescribed upregulation of enzymes associated with oxidative
damage, including gp91phox, iNOS, and COX-2 (Bao et al.,
2004a, 2004b, 2005). Administration of the PDE4-I reduced
these responses substantially, as well as the ensuing production
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FIG. 7. Phosphodiesterase type 4 inhibitor (PDE4-I) treatment at 0.5 mg/kg preserves tissue at 8 weeks after SCI. The top
panel shows photomicrographs of Luxol fast blue- and hematoxylin and eosin (H&E)-stained cross-sections of spinal cord
from control (A) and PDE4-I-treated rats (B). Normal-appearing white matter used for quantification is outlined with a green
line. Note the greater overall tissue preservation in the spinal cord of the PDE4-I-treated rat (scale bar = 500 lm). The volumes
of gray matter, white matter, and lesion size and neuron number within the T3–T5 spinal cord of controls (n = 5) and PDE4-Itreated rats (n = 5) are plotted in the lower panel. PDE4-I treatment significantly increased the white matter volume ( p = 0.004
by Student’s t-test), but did not significantly change gray matter, lesion volume, or neuron number. The coefficient of error for
the counts of neurons ranged from 0.024–0.048 among the control and PDE4-I-treated rats, and the average value was 0.032
(SCI, SCI control injured; SCI + PDE4-I, treated injured).
of free radicals. Importantly, reductions in inflammatory and
oxidative processes by PDE4-I were accompanied by a significant abrogation of lipid peroxidation at 24 and 72 h after SCI,
as well as white-matter preservation at 8 weeks. Neuroprotective effects reported after treatment with rolipram include
sparing of oligodendrocytes, increased central myelination
(consistent with our white-matter sparing), and improved
neurotransmission through the ventrolateral funiculus (Beaumont et al., 2009; Pearse et al., 2004a; Whitaker et al., 2008).
These could be downstream benefits of the reduction of inflammation and oxidative injury caused by the PDE4 inhibitor.
Prior to our investigation with IC486051, we conducted a small
pilot study using rolipram and found that it limited intraspinal
inflammation and oxidative injury after SCI (Weaver and Bao,
unpublished observations). The anti-inflammatory and antioxidant effects of PDE4 inhibition in our study may also have
translated into oligodendrocyte preservation and improved
neurotransmission, as possible downstream mechanisms for
the functional improvements that we observed.
The early protective actions of the PDE4-I led to long-term
improvements in locomotor function and a reduction in
neuropathic pain, similarly to effects we have observed with
other neuroprotective treatments (Fleming et al., 2008; Gris
et al., 2004). Previously, another PDE4 inhibitor, rolipram,
when administered subcutaneously for 2 weeks, improved
BBB scores by about 2 points (from approximately 10–12) at
5 weeks after injury when delivery was initiated within
15 min of a moderate T8 thoracic SCI (Pearse et al., 2004a).
In the more severe injury model employed in the current
study, the 1-point improvement in BBB scores observed with
the PDE4-I following a 72-h treatment protocol compares

favorably with the outcome of the protracted treatment after
a milder injury.
We demonstrated no consistent statistically significant differences between the three doses of the PDE4-I tested. But, in
contrast the 0.5- and 1.0-mg/kg doses, the 3.0-mg/kg dose had
a smaller anti-inflammatory effect at 24 h, and no anti-inflammatory effect by 72 h after SCI. We opted to test only the doses
with more robust actions in later histological and behavioral
investigations. A lack of persistent anti-inflammatory action
with dose escalation may be due to the putative activation of
opposing intracellular signaling pathways associated with the
many targets of cAMP (Borland et al., 2009). Moreover, increased cAMP and inhibited PDE4 activity have been shown to
have proinflammatory actions in certain circumstances (Hertz
et al., 2009), and perhaps at high doses, this kind of action
confounded any positive effects. Although both 0.5 and
1.0 mg/kg of the PDE4-I ameliorated mechanical allodynia
(neuropathic pain) for the duration of the study, the lowest
dose had the most robust effect on locomotor function. These
outcomes correlated with significant sparing of white matter at
8 weeks after the injury. The lack of a significant reduction in
lesion volume was consistent with the lack of grey matter and
neuronal sparing. A conclusion from these findings may be
that, rather than rescue of neurons and glia, sparing of axons
across the lesion or promotion of their sprouting is a more
important factor in the neuroprotection afforded by this treatment. Labeling studies to examine the integrity of descending
axon systems would help to answer this question. Moreover,
the significant white-matter sparing that we observed is consistent with the protection of oligodendrocytes, and greater
central myelination and neurotransmission, outcomes reported
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by others after treatment with the PDE4 inhibitor rolipram
(Beaumont et al., 2009; Pearse et al., 2004a; Whitaker et al.,
2008). Another mechanism by which the acute PDE4-I treatment could promote regeneration of these axons would be by
protecting against secondary damage and scarring within the
lesion site due to reduction of oxidative activity. In our study,
direct treatment effects would no longer be present during the
critical periods for regeneration.
Increased cAMP concentrations have been implicated in
the inhibition of proinflammatory cell functions such as chemotaxis, degranulation, superoxide anion generation, release
of IL-8, and phagocytosis in neutrophils (Ottonello et al., 1995;
Pearse et al., 2004a; Pryzwansky and Madden, 2003; Rossi
et al., 1998). Furthermore, monocyte adhesion and migration
are inhibited by high cAMP levels. Phagocytosis and nitric
oxide production in macrophages are also downregulated
(Aronoff et al., 2005; Rossi et al., 1998; Zhu et al., 2001). In
addition, an increase in cAMP decreases the expression of
adhesion molecules (CD11b/CD18/L-selectin), and adhesion
to other cells, and disrupts chemokine-induced chemotaxis
(Derian et al., 1995; Harvath et al., 1991). cAMP is thus a key
intracellular second messenger that at increased levels can
have anti-inflammatory and tissue-protective effects. cAMP
levels are increased upon activation of the membrane
G-protein coupled receptor subunit Gsa, that in turn activates
adenylyl cyclase (Wiemelt et al., 1997). Adenylyl cyclase has a
host of downstream effector systems important in cell signaling (Beavo and Brunton, 2002). cAMP is highly regulated
in neutrophils and monocytes/macrophages through PDEmediated cAMP degradation. Three of the four genes belonging to the PDE4 family (namely, PDE4A, PDE4B, and
PDE4D) are ubiquitously expressed in inflammatory cells
(Ariga et al., 2004). The PDE4 inhibitor treatment used in this
study, IC486051, would prevent PDE4 from hydrolyzing
cAMP, thus maintaining intracellular cAMP levels, an important stabilizing force when they are significantly reduced
after CNS injury (Atkins et al., 2007; Pearse et al., 2004b).
Unfortunately, we did not measure cAMP directly in the
leukocytes of our rats, and must infer that the inhibition of
PDE4 did stabilize or increase cAMP in these and other cells.
Increased cAMP signaling contributes to the inhibition of
inflammatory responses by several possible mechanisms.
Some evidence suggests that cAMP signaling is regulated by a
protein kinase A (PKA)-dependent pathway. PDE4A, PDE4B,
and PDE4D have been targeted and co-localized with the
catalytic subunit of PKA in the forming phagosome (Pryzwansky and Madden, 2003). PKA phosphorylates many
downstream targets that lead to inhibition of cell activation.
For example, the cAMP-PKA pathway negatively regulates
Rac activity, leading to reduced neutrophil migration (Nagasawa et al., 2005). PKA contributes to the suppression of
TNF-a production (Pearse et al., 2004a; Zhu et al., 2001), and
inhibition of apoptosis through the MAPK-ERK pathway
(Martin et al., 2001). PKA also partially mediates inhibition of
the NADPH oxidase assembly through a RAP1a-mediated
pathway (Ottonello et al., 1995). cAMP may also foster inhibitory cellular effects by directly activating phospholipase
D, arachidonic acid, or Ca2 + influx (Agwu et al., 1991; Pryzwansky and Madden, 2003). Aronoff and associates (Aronoff
et al., 2005) showed that direct cAMP activation of the guanine
exchange protein Epac-1 contributes to inhibition of macrophage phagocytic function, without the involvement of PKA.
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The anti-inflammatory potential of other PDE4-specific
inhibitors such as rolipram has been evaluated in other disease models. Rolipram delays the onset and severity of experimental autoimmune encephalopathy (EAE), an animal
model of multiple sclerosis, by delaying the peak in levels of
TNF-a and IL-6 produced by Th-1 lymphoctes (Dinter et al.,
2000; Zhu et al., 2001). In addition, rolipram passes the blood–
brain barrier readily and reduces its permeability in the spinal
cord of mice with EAE, causing reduced tissue edema and
inflammatory cell infiltration (Zhu et al., 2001). Furthermore,
superoxide production and elastase release by neutrophils
are inhibited by rolipram through cAMP-dependent resequestration of cytosolic Ca2 + (Anderson et al., 1998). In
addition, rolipram inhibits the expression of the adhesion
molecules CD11b and L-selectin on platelet activating factorstimulated neutrophils and eosinophils in vitro (Berends et al.,
1997). As described above, sustained treatment with rolipram
improves the outcomes of SCI (Beaumont et al., 2009; Iannotti
et al., 2010; Pearse et al., 2004a), but clinical studies have revealed that it has major negative side effects in humans
(Bruno et al., 2004; Zhu et al., 2001). RP-73401, Ariflo, and
CDP-840 are newly-developed selective PDE4 inhibitors with
higher potency and lower toxicity that may have potential for
treating SCI (Bruno et al., 2004).
In conclusion, these findings emphasize the value of PDE4
inhibition in the treatment of SCI. Not only does it promote
cellular sparing, myelination, regeneration, and functional
recovery when given for long periods as described previously
(Beaumont et al., 2009; Bretzner et al., 2010; Iannotti et al.,
2010; Nikulina et al., 2004; Pearse et al., 2004a; Whitaker et al.,
2008), but early, brief treatment with the PDE4 inhibitor
IC486051 proved to be a useful anti-inflammatory strategy
that yielded substantial neuroprotection and improved neurological outcomes. An appealing treatment paradigm could
be an acute, brief treatment with doses of a PDE4 inhibitor to
provide early neuroprotection and sparing of damaged tissue,
followed by a more sustained, lower-dose treatment to supply
further neuroprotection and facilitate regeneration.
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